The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines

Raman spectroscopy (RS) is an optical technique that provides an objective method of pathological diagnosis based on the molecular composition of tissue. Studies have shown that the technique can accurately identify and grade prostatic adenocarcinoma (CaP) in vitro. This study aimed to determine whether RS was able to differentiate between CaP cell lines of varying degrees of biological aggressiveness. Raman spectra were measured from two well-differentiated, androgen-sensitive cell lines (LNCaP and PCa 2b) and two poorly differentiated, androgen-insensitive cell lines (DU145 and PC 3). Principal component analysis was used to study the molecular differences that exist between cell lines and, in conjunction with linear discriminant analysis, was applied to 200 spectra to construct a diagnostic algorithm capable of differentiating between the different cell lines. The algorithm was able to identify the cell line of each individual cell with an overall sensitivity of 98% and a specificity of 99%. The results further demonstrate the ability of RS to differentiate between CaP samples of varying biological aggressiveness. RS shows promise for application in the diagnosis and grading of CaP in clinical practise as well as providing molecular information on CaP samples in a research setting.

[1]  J. Edward Jackson,et al.  A User's Guide to Principal Components. , 1991 .

[2]  N Ramanujam,et al.  Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo , 1996, Lasers in surgery and medicine.

[3]  C. Kendall,et al.  Optical diagnostics in urology: current applications and future prospects , 2003, BJU international.

[4]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[5]  D. Paulson,et al.  Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. , 1980, Progress in clinical and biological research.

[6]  N. Stone Raman spectroscopy of biological tissue for application in optical diagnosis of malignancy , 2001 .

[7]  Z. Darżynkiewicz,et al.  Flow cytometry in analysis of cell cycle and apoptosis. , 2001, Seminars in hematology.

[8]  J. Edward Jackson,et al.  A User's Guide to Principal Components: Jackson/User's Guide to Principal Components , 2004 .

[9]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[10]  N. Maitland,et al.  In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates , 2000, British Journal of Cancer.

[11]  J. E. Jackson A User's Guide to Principal Components , 1991 .

[12]  Hugh Barr,et al.  Near‐infrared Raman spectroscopy for the classification of epithelial pre‐cancers and cancers , 2002 .

[13]  Joseph D. Schmidt Clinical diagnosis of prostate cancer , 1992, Cancer.

[14]  N Stone,et al.  The use of Raman spectroscopy to identify and grade prostatic adenocarcinoma in vitro , 2003, British Journal of Cancer.

[15]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[16]  G. Risbridger,et al.  An in vivo model of prostate carcinoma growth and invasion in bone , 2002, Cell and Tissue Research.

[17]  Ş. Özdamar,et al.  Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas , 2006, International Urology and Nephrology.

[18]  D. Johnston,et al.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Eric R. Ziegel,et al.  Chemometrics: Statistics and Computer Application in Analytical Chemistry , 2001, Technometrics.

[20]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.